KR100534556B1 - 알파1g 단백질의 기능을 억제하여 간질을 일으키지 않게하는 방법 - Google Patents
알파1g 단백질의 기능을 억제하여 간질을 일으키지 않게하는 방법 Download PDFInfo
- Publication number
- KR100534556B1 KR100534556B1 KR10-2001-0066257A KR20010066257A KR100534556B1 KR 100534556 B1 KR100534556 B1 KR 100534556B1 KR 20010066257 A KR20010066257 A KR 20010066257A KR 100534556 B1 KR100534556 B1 KR 100534556B1
- Authority
- KR
- South Korea
- Prior art keywords
- alpha
- mice
- mouse
- gene
- calcium ion
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 94
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title claims abstract description 14
- 206010015037 epilepsy Diseases 0.000 title abstract description 32
- 241000699670 Mus sp. Species 0.000 claims abstract description 68
- 108090000312 Calcium Channels Proteins 0.000 claims abstract description 55
- 102000003922 Calcium Channels Human genes 0.000 claims abstract description 55
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 32
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 238000011830 transgenic mouse model Methods 0.000 claims description 24
- 239000013598 vector Substances 0.000 claims description 22
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 21
- 241000699660 Mus musculus Species 0.000 claims description 19
- 210000002459 blastocyst Anatomy 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 6
- 108020004440 Thymidine kinase Proteins 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 2
- 108700026220 vif Genes Proteins 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 238000010363 gene targeting Methods 0.000 abstract description 9
- 239000011575 calcium Substances 0.000 abstract description 7
- 230000007246 mechanism Effects 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 5
- 229910052791 calcium Inorganic materials 0.000 abstract description 5
- 230000003449 preventive effect Effects 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- 102000004310 Ion Channels Human genes 0.000 abstract description 2
- 108090000862 Ion Channels Proteins 0.000 abstract description 2
- 238000010171 animal model Methods 0.000 abstract description 2
- 239000012268 protein inhibitor Substances 0.000 abstract description 2
- 229940121649 protein inhibitor Drugs 0.000 abstract description 2
- 206010010904 Convulsion Diseases 0.000 description 81
- 235000018102 proteins Nutrition 0.000 description 39
- 210000002569 neuron Anatomy 0.000 description 35
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 23
- 229910001424 calcium ion Inorganic materials 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 230000000694 effects Effects 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 13
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 229960004979 fampridine Drugs 0.000 description 11
- 238000010304 firing Methods 0.000 description 11
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 10
- 230000000112 colonic effect Effects 0.000 description 9
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 9
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 8
- 229960000794 baclofen Drugs 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000001103 thalamus Anatomy 0.000 description 8
- 238000002105 Southern blotting Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 210000004291 uterus Anatomy 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 230000000542 thalamic effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 206010061334 Partial seizures Diseases 0.000 description 5
- 230000003542 behavioural effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000004880 explosion Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000001314 paroxysmal effect Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000036982 action potential Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 230000036390 resting membrane potential Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001360 synchronised effect Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 206010053398 Clonic convulsion Diseases 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 208000003443 Unconsciousness Diseases 0.000 description 3
- 208000028311 absence seizure Diseases 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 230000000573 anti-seizure effect Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000009172 bursting Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002308 embryonic cell Anatomy 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 230000007849 functional defect Effects 0.000 description 3
- 230000002102 hyperpolarization Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000003461 thalamocortical effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- BWXCECYGGMGBHD-GRTNUQQKSA-M (6r)-6-[(5s)-6,6-dimethyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-6-ium-5-yl]-6h-furo[3,4-g][1,3]benzodioxol-8-one;bromide Chemical compound [Br-].O([C@H]1[C@@H]2C3=CC=4OCOC=4C=C3CC[N+]2(C)C)C(=O)C2=C1C=CC1=C2OCO1 BWXCECYGGMGBHD-GRTNUQQKSA-M 0.000 description 2
- 101100477360 Arabidopsis thaliana IPSP gene Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 208000034308 Grand mal convulsion Diseases 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028347 Muscle twitching Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 208000037158 Partial Epilepsies Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010040703 Simple partial seizures Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 208000028329 epileptic seizure Diseases 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000001709 ictal effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000009191 jumping Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000003412 4 aminobutyric acid B receptor blocking agent Substances 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 101000768857 Arabidopsis thaliana 3-phosphoshikimate 1-carboxyvinyltransferase, chloroplastic Proteins 0.000 description 1
- 206010003628 Atonic seizures Diseases 0.000 description 1
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000033001 Complex partial seizures Diseases 0.000 description 1
- OIMUAKUQOUEPCZ-WHFBIAKZSA-N Cys-Asn-Gly Chemical compound SC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIMUAKUQOUEPCZ-WHFBIAKZSA-N 0.000 description 1
- 206010016173 Fall Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HKXSZKJMDBHOTG-CIUDSAMLSA-N Lys-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN HKXSZKJMDBHOTG-CIUDSAMLSA-N 0.000 description 1
- HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010034759 Petit mal epilepsy Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- AEGUWTFAQQWVLC-BQBZGAKWSA-N Ser-Gly-Arg Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O AEGUWTFAQQWVLC-BQBZGAKWSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 208000003554 absence epilepsy Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000001849 anti-absence effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 108010089442 arginyl-leucyl-alanyl-arginine Proteins 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000001787 epileptiform Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000036749 excitatory postsynaptic potential Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000036734 inhibitory postsynaptic potential Effects 0.000 description 1
- 210000002425 internal capsule Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229960004438 mibefradil Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001423 neocortical effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000004001 thalamic nuclei Anatomy 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (14)
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- T-타입 칼슘 이온 통로의 알파1G 단백질이 발현되지 않는 알파1G -/- 유전자형을 갖는 동형접합체(homozygote) 유전자 변이 생쥐(transgenic mouse).
- 제 7항에 있어서, 생쥐는 무스 무쿨러스(Mus Musculus)인 것을 특징으로 하는 유전자 변이 생쥐.
- 제 7항 또는 제 8항에 있어서, 알파1G 유전자의 N-말단 82-118 부위가 결실된 유전자 변이 생쥐.
- (1) T-타입 칼슘 이온 통로의 알파1G 유전자에 대한 적중벡터(targeting vector)를 생쥐 배아간세포에 도입하는 단계;(2) 상기 배아간세포를 포배아의 포배강에 주입하여 키메라 생쥐(chimera mouse)를 얻는 단계;(3) 상기 키메라 생쥐를 정상 생쥐와 교배시켜 알파1G +/- 유전자형을 갖는 이형접합체(heterozygote) 생쥐를 얻는 단계; 및(4) 상기 이형접합체 생쥐의 암컷과 수컷을 교배시키는 단계로 구성되는 알파1G -/- 유전자형을 갖는 동형접합체(homozygote) 유전자 변이 생쥐의 제조방법.
- 제 10항에 있어서, 적중벡터는 PGK-neo 카셋트를 포함하는 것을 특징으로 하는 유전자 변이 생쥐의 제조방법.
- 제 10항 또는 제 11항에 있어서, 적중벡터는 알파1G 유전자에 대한 상동 절편 2개, PGK-neo 카셋트 및 3' 말단에 위치하는 티미딘 키나제(thymidine kinase) 유전자 카셋트를 포함하는 것을 특징으로 하는 유전자 변이 생쥐의 제조방법.
- 알파1G +/- 유전자형을 갖는 이형접합체(heterozygote) 유전자 변이 생쥐(transgenic mouse)의 수정란(수탁번호 : KCTC 10086 BP).
- 제 13항의 수정란을 대리모에 이식하여 알파1G +/- 유전자형을 갖는 이형접합체(heterozygote) 유전자 변이 생쥐를 얻고, 이형접합체 유전자 변이생쥐의 암컷과 수컷을 교배시켜 알파1G -/- 유전자형을 갖는 동형접합체(homozygote) 유전자 변이 생쥐의 제조방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0066257A KR100534556B1 (ko) | 2001-10-26 | 2001-10-26 | 알파1g 단백질의 기능을 억제하여 간질을 일으키지 않게하는 방법 |
US10/493,376 US20060025397A1 (en) | 2001-10-26 | 2002-01-18 | Method of resistance of epilepsy by suppressing the function of alpha 1g protein |
PCT/KR2002/000087 WO2003035698A1 (en) | 2001-10-26 | 2002-01-18 | Method for resistance of epilepsy by suppressing the function of alpha 1g protein |
US11/986,671 US7626076B2 (en) | 2001-10-26 | 2007-11-23 | Transgenic mouse whose genome comprises a homozygous disruption of its α1G gene, a method of preparing the same and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0066257A KR100534556B1 (ko) | 2001-10-26 | 2001-10-26 | 알파1g 단백질의 기능을 억제하여 간질을 일으키지 않게하는 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030034605A KR20030034605A (ko) | 2003-05-09 |
KR100534556B1 true KR100534556B1 (ko) | 2005-12-08 |
Family
ID=19715411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2001-0066257A KR100534556B1 (ko) | 2001-10-26 | 2001-10-26 | 알파1g 단백질의 기능을 억제하여 간질을 일으키지 않게하는 방법 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20060025397A1 (ko) |
KR (1) | KR100534556B1 (ko) |
WO (1) | WO2003035698A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023022504A1 (ko) | 2021-08-17 | 2023-02-23 | 한국과학기술원 | Cav3.1 유전자를 표적으로 하는 안티센스 올리고뉴클레오타이드 및 그의 용도 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7626076B2 (en) * | 2001-10-26 | 2009-12-01 | Orient Bio., Inc. | Transgenic mouse whose genome comprises a homozygous disruption of its α1G gene, a method of preparing the same and use thereof |
KR100746585B1 (ko) * | 2004-05-04 | 2007-08-08 | 한국과학기술연구원 | 자극추구형 성격과 알코올 선호도가 증가된α1GT-타입채널 유전자 적중생쥐 및 알파1G 유전자를조절하여 기분장애를 치료하는 방법 |
WO2008138126A1 (en) * | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Bicyclic pyrimidine derivatives as calcium channel blockers |
US20090012010A1 (en) * | 2007-05-18 | 2009-01-08 | Neuromed Phramaceuticals Ltd. | Amino acid derivatives as calcium channel blockers |
WO2009132453A1 (en) * | 2008-04-28 | 2009-11-05 | Neuromed Pharmaceuticals Ltd. | Cyclylamine derivatives as calcium channel blockers |
WO2009132452A1 (en) * | 2008-04-28 | 2009-11-05 | Neuromed Pharmaceuticals Ltd. | Diaryl-cyclylalkyl derivatives as calcium channel blockers |
WO2009132454A1 (en) * | 2008-04-28 | 2009-11-05 | Neuromed Pharmaceuticals Ltd. | Di-t-butylphenyl piperazines as calcium channel blockers |
US8377968B2 (en) | 2008-06-02 | 2013-02-19 | Zalicus Pharmaceuticals, Ltd. | N-piperidinyl acetamide derivatives as calcium channel blockers |
US20090298834A1 (en) * | 2008-06-02 | 2009-12-03 | Hassan Pajouhesh | 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers |
ES2786298T3 (es) | 2011-03-03 | 2020-10-09 | Zalicus Pharmaceuticals Ltd | Inhibidores de benzimidazol del canal de sodio |
DK2915879T3 (en) * | 2012-10-31 | 2018-05-22 | Eisai R&D Man Co Ltd | NEURAL STAMCELLE WITH INCREASED PASSENGER, PROCEDURE FOR PREPARING THE NEURAL STAMCELLE WITH INCREASED PASSENGER AND PROCEDURE FOR CULTIVATING THE NEURAL STAMCELLE TO INCREASE PASSAGE NECAL |
EP2961403A4 (en) | 2013-03-01 | 2016-11-30 | Zalicus Pharmaceuticals Ltd | HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL |
KR20220066252A (ko) | 2019-07-11 | 2022-05-24 | 프락시스 프리시젼 메디신즈, 인크. | T형 칼슘 채널 조절제의 제형 및 이의 사용 방법 |
-
2001
- 2001-10-26 KR KR10-2001-0066257A patent/KR100534556B1/ko active IP Right Grant
-
2002
- 2002-01-18 WO PCT/KR2002/000087 patent/WO2003035698A1/en not_active Application Discontinuation
- 2002-01-18 US US10/493,376 patent/US20060025397A1/en not_active Abandoned
Non-Patent Citations (4)
Title |
---|
1쪽 요약, J Physiol, 2001 Apr, 532(Pt 1), 205-216, Sanabria ER * |
Biull Eksp Biol Med, 1992 Apr, 113(4), 347-349, Kryzhanovskii GN * |
Chphalalgia, 2000 Oct, 20(8), 740-747, Gorji A * |
Neuropharmacol.,vol.39(7), pp.1254-1266, 2000 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023022504A1 (ko) | 2021-08-17 | 2023-02-23 | 한국과학기술원 | Cav3.1 유전자를 표적으로 하는 안티센스 올리고뉴클레오타이드 및 그의 용도 |
Also Published As
Publication number | Publication date |
---|---|
KR20030034605A (ko) | 2003-05-09 |
US20060025397A1 (en) | 2006-02-02 |
WO2003035698A1 (en) | 2003-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Watase et al. | A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration | |
KR100534556B1 (ko) | 알파1g 단백질의 기능을 억제하여 간질을 일으키지 않게하는 방법 | |
Awasaki et al. | The Drosophila trio plays an essential role in patterning of axons by regulating their directional extension | |
AU2017245099B2 (en) | Anti-Ryk antibodies and methods of using the same | |
US7626076B2 (en) | Transgenic mouse whose genome comprises a homozygous disruption of its α1G gene, a method of preparing the same and use thereof | |
JP2009529490A (ja) | ニューロンの可塑性および再生を増強するための組成物および方法 | |
Shandala et al. | The Drosophila retained/dead ringer gene and ARID gene family function during development | |
Camus et al. | Gene trap insertion reveals two open reading frames in the mouse SSeCKS gene: the form predominantly detected in the nervous system is suppressed by the insertion while the other, specific of the testis, remains expressed | |
KR100979438B1 (ko) | 불안장애 치료제 효과 검증 모델 동물로서의 PLCβ4돌연변이 생쥐 | |
KR100873400B1 (ko) | N-타입 칼슘 채널의 활성을 억제함으로써 우울증을감소시키는 방법 | |
KR100861696B1 (ko) | 우울증 치료제의 스크리닝 방법 | |
KR101144326B1 (ko) | 압상스 간질 치료제 효과 검증 동물모델로서 PLCβ4 유전자 결손 마우스 | |
KR100372843B1 (ko) | 간질이유발된변이형생쥐및이의제조방법 | |
WO1999006034A1 (en) | Coup-tfi directed therapies in the treatment of disease | |
WO2007135570A2 (en) | Pink1 deficient animals, screening methods, and related therapeutics | |
EP1619248A1 (en) | Mouse with deficiency of glutamate transporter glast function | |
US20070162989A1 (en) | Methods and compositions for treating motor neuron associated disorders | |
KR100635878B1 (ko) | hNCTm 유전자를 발현하는 형질전환 치매 마우스 | |
KR100514090B1 (ko) | Ncx2 단백질의 활성을 억제함으로써 학습능력 및기억력을 증진시키는 방법 | |
KR101766441B1 (ko) | 헌팅틴 유전자의 뇌 시공간 특이적 발현 방법 및 이를 이용한 동물 모델 | |
CN114990160A (zh) | 一种Navβ2-ICD低表达转基因鼠模型的构建方法及其应用 | |
WO2003046172A2 (en) | Alzheimer’s disease model | |
van't Padje | Zebrafish as a model to study human disease: Functional studies of the FXR proteins | |
Osterloh | dSarm/Sarm1 Governs a Conserved Axon Death Program: A Dissertation | |
JPWO2004016083A1 (ja) | 球脊髄性筋萎縮症の病態を再現する非ヒト動物、及び球脊髄性筋萎縮症治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
N231 | Notification of change of applicant | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121109 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20131030 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150917 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20160928 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20170908 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20180910 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20191002 Year of fee payment: 15 |